EMA Advisory Group Issues Positive Opinion on Lilly's Donanemab for Treatment of Early Alzheimer Disease
The European Commission is expected to make a final regulatory decision on the anti-amyloid therapy in the coming months, Lilly said.
7 Common Causes of Dementia: A Topline Review
The brain changes that lead to cognitive and behavioral changes referred to as dementia have multiple potential etiologies; not all dementia is Alzheimer disease.
Late-Life Mood Disorders May Represent Prodromal States of Dementia: Daily Dose
Your daily dose of the clinical news you may have missed.
AI-Generated Dermatologic Images Show Poor Diagnostic Accuracy, Underrepresent Skin of Color
In response to the prompt, "Generate a photo of a person with [skin condition]," 3 of 4 generative AI models significantly underrepresented diverse skin tones.
Make It Routine: Screening for Cognitive Decline in Primary Care
Listen to our latest podcast episode to discover how early dementia detection enhances care and quality of life, with actionable strategies for primary care teams to implement now.
Influenza Vaccination Reduces Disease Burden in Both Vaccinated and Unvaccinated, Modeling Study Finds
Vaccination lowered influenza cases by about 33% to 42% in seasonal flu setups with 40% vaccine effectiveness, researchers reported.
FDA Grants Fast Track Designation for Sprout's Flibanserin to Treat HSDD in Postmenopausal Women
Low sexual desire affects up to 40% of women across the lifespan but currently there is no treatment option for those beyond their reproductive years.
FDA Advisory Panel Calls for Revised Class Labeling for Menopausal Hormone Replacement Therapy
Experts reviewed data from the 2002 Women's Health Initiative study that prompted class warnings for estrogen-containing therapies and called for changes, education.
GLP-1 RAs vs Metformin Significantly Reduce Risk of Dementia in Adults with Type 2 Diabetes
Both metformin and GLP-1 RAs have been studies for their neuroprotective effects; this study is the first head-to-head investigation and supports further research.
Real-World GLP-1 RA Discontinuation Tied to Modest Weight Loss: Daily Dose
FDA Approves Delgocitinib, First Treatment for Adults With Moderate to Severe Chronic Hand Eczema
The nonsteroidal topical pan-JAK inhibitor provides a potent treatment option for adults with CHE who have not responded to corticosteroids or cannot tolerate them.
The Weekly Dose: Insights on Atopic Dermatitis, Menopause Care, Cancer Screening, and Weight Loss Therapy
Insights on an FDA-approved multi-cancer detection test, the impact of obesity pharmacotherapy adherence on weight loss outcomes, and more.
Refined Digital Tools Have Revolutionized the Return on Cognitive Screening: Investigator Rodney Swenson, PhD, Explains
Swenson focused on the precision afforded by digital tools in assessing human behavior and identifying preclinical signs of cognitive impairment.
Thimerosal to Be Eliminated from All US Vaccines, HHS Announces
HHS secretary Robert F Kennedy, Jr, today formally agreed with the recent ACIP recommendation to eliminate the already largely discontinued preservative.
Muscle Loss During GLP-1 Therapy Top Concern for Patients Using the Antiobesity Medications
Individuals on GLP-1 therapy express significant concern about muscle loss, prompting lifestyle changes and highlighting the need for informed primary care guidance.
Obesity and Cardiovascular Disease Management: 3 Pearls for Primary Care
Monu Khanna, MD, offers 3 takeaways for primary care: address obesity as root cause, reduce stigma, and explore new treatments to reduce cardiovascular risk.
Efficacy of Apnimed's Novel Oral Formulation Targeting OSA Confirmed in Second Phase 3 Trial
Apnimed's first-in-class anti-apneic AD109 increases upper airway muscle tone during sleep; the company plans to file an NDA with the FDA in early 2026.
Cycling Tied to 19% Lower Risk of Dementia: Daily Dose
Obesity Is a Chronic Disease—Start the Conversation in Primary Care, Says Monu Khanna, MD
Dr Khanna discusses why obesity should be treated as a chronic disease in primary care and how early conversations can help prevent cardiometabolic complications.
What is Driving Type 2 Diabetes in the US?
Type 2 diabetes and its high and rising rates in the US are the result of a perfect storm of converging systemic, behavioral, environmental, and economic factors.
